Oncolytic virus startup TILT raises €22M to advance cancer therapies

Finland-based TILT Biotherapeutics announced today it raised €22 million in the final close of a second round of financing to push its oncolytic virus pipeline into Phase II trials. The company raised €10 million in the first round in June of last year.